These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 9361936

  • 1. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R.
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [Abstract] [Full Text] [Related]

  • 2. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database.
    Snydman DR, Kistler KD, Ulsh P, Bergman GE, Vensak J, Morris J.
    Clin Transplant; 2011 Oct; 25(4):E455-62. PubMed ID: 21504474
    [Abstract] [Full Text] [Related]

  • 3. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.
    Clin Transplant; 2008 Oct; 22(1):89-97. PubMed ID: 18217909
    [Abstract] [Full Text] [Related]

  • 4. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B.
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [Abstract] [Full Text] [Related]

  • 5. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR.
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [Abstract] [Full Text] [Related]

  • 6. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation.
    Fisher RA, Kistler KD, Ulsh P, Bergman GE, Morris J.
    Transpl Infect Dis; 2012 Apr; 14(2):121-31. PubMed ID: 21883757
    [Abstract] [Full Text] [Related]

  • 7. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR, Werner BG, Dougherty NN, Griffith J, Rohrer RH, Freeman R, Jenkins R, Lewis WD, O'Rourke E.
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, Lohmann R, Knoop M, Lobeck H, Schlag H, Keck H, Settmacher U, Bechstein WO, Neuhaus PJ.
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
    Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, Rohrer RH, Freeman R, Jenkins R, Lewis WD, Hammer S, O'Rourke E, Grady GF, Fawaz K, Kaplan MM, Hoffman MA, Katz AT, Doran M, Boston Center for Liver Transplantation CMVIG Study Group.
    Ann Intern Med; 1993 Nov 15; 119(10):984-91. PubMed ID: 8214995
    [Abstract] [Full Text] [Related]

  • 10. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 11. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep 15; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 12. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
    George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH.
    Am J Med; 1997 Aug 15; 103(2):106-13. PubMed ID: 9274893
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
    Snydman DR, Kistler KD, Ulsh P, Morris J.
    Transplantation; 2010 Dec 27; 90(12):1432-8. PubMed ID: 21076378
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 15. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR, Fullerton DA, Campbell DN, Leone S, Diercks MJ, Fisher JH, Badesch DB, Grover FL.
    Transplant Proc; 1994 Oct 27; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Oct 27; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 17. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP, Kowdley KV, Emond MJ, Barr D, Marsh CL, Carithers RL, Perkins JD.
    Clin Transplant; 1997 Aug 27; 11(4):328-33. PubMed ID: 9267724
    [Abstract] [Full Text] [Related]

  • 18. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA, O'Kelly P, Spencer S, Hickey DP, Conlon PJ, Walshe JJ.
    Ren Fail; 2008 Aug 27; 30(2):141-6. PubMed ID: 18300112
    [Abstract] [Full Text] [Related]

  • 19. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I, Hsaiky L, Brown K, Abouljoud M.
    Liver Transpl; 2008 Jan 27; 14(1):66-72. PubMed ID: 18161842
    [Abstract] [Full Text] [Related]

  • 20. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Levey AS.
    N Engl J Med; 1987 Oct 22; 317(17):1049-54. PubMed ID: 2821397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.